Exchange Bulletin
SciVac Therapeutics Inc. (VAC) To Trade On Toronto Stock Exchange
CHANGES IN STOCK LIST
BACKDOOR LISTING
SciVac Therapeutics Inc. The common shares (“Shares”) of SciVac Therapeutics Inc. (the “Company”) will be listed and posted for trading in the Industrial category under the trading information set out below at the opening on Tuesday, July 14, 2015.
| Stock Symbol: "VAC" | CUSIP: 783899 10 7 | Trading Currency: CDN$ |
Designated Market Maker: Questrade Inc.
Other Markets: None
The foregoing results from a recently completed plan of arrangement (the "Arrangement") involving the Levon Resources Ltd. (“Levon”), 1027949 B.C. Ltd. (“New Levon”) and SciVac Ltd., among others. Pursuant to the Arrangement, Levon acquired all of the issued and outstanding common shares of SciVac Ltd., changed its name to SciVac Therapeutics Inc. and the holders of the common shares of Levon (each, a “Levon Share”) will receive for each Levon Share:
- 0.5 of one common share of New Levon; and
- one common share of the Company.
No certificates representing fractional Shares of the Company or common shares of New Levon will be issued under the Arrangement. Any fractional shares issuable pursuant to the Arrangement will be rounded down to the nearest whole number.
It is understood Letters of Transmittal were mailed to shareholders of Levon on or about May 8, 2015 requesting them to return the duly completed and executed Letters of Transmittal, together with the certificates representing their Levon Shares to Valiant Trust Company at its principal offices in Toronto or Vancouver in order to receive the consideration to which they are entitled.
See elsewhere in today’s Toronto Stock Exchange (“TSX”) Bulletins for details regarding the listing of the common shares of New Levon in substitution for the Levon Shares.
Additional information about the Arrangement and the Company may be found in the Management Information Circular of Levon dated May 1, 2015 which is available at www.SEDAR.com.
The Company is subject to the reporting requirements of Section 501 of the TSX Company Manual.
Description of the Company
An application has been granted for the original listing in the Industrial category of 832,259,382 Shares, of which 756,599,439 Shares are issued and outstanding and 75,659,943 Shares are reserved for issuance.
| Head Office Address: | 13 Gad Feinstein Road Rehovot 76100, Israel |
| Head Office Telephone Number: | 786-459-1831 |
| Fax Number: | 972-8-948-0660 |
| Email Address: | jmartin@scivac.us |
| Website: | www.scivac.us |
| Investor Relations: | Curtis A. Lockshin Tel: 781-883-6036 Email: lockshin@scivac.us James J. Martin Tel: 305-842-3767 Email: jmartin@scivac.us |
| Chief Financial Officer: | James J. Martin |
| Corporate Secretary: | Shayla Forster |
| Incorporation: | Levon was incorporated under the Company Act (British Columbia) on April 9, 1965 under the name “Alice Arm Molybdenum Co. Ltd. (N.P.L.)”. On October 21, 1965, the Company changed its name to “Alice Arm Mining Ltd. (N.P.L.)” and on July 13, 1975, to “New Congress Resources Ltd. (N.P.L.)”. On July 29, 1981 the Company changed its name to “New Congress Resources Ltd.”, and on January 12, 1983, to “Levon Resources Ltd.”. On July 15, 2004, the Company transitioned under the Business Corporations Act (British Columbia) and on July 9, 2015 changed its name to “SciVac Therapeutics Inc.” |
| Fiscal Year End: | December 31 |
| Nature of Business: | The Company is in the business of developing, producing, and marketing products to treat infectious and immune diseases. The Company’s lead product is Sci-B-Vac, a third generation Hepatitis B vaccine. |
| Transfer Agent & Registrar: | Valiant Trust Company at its principal offices in Toronto, Calgary and Vancouver. |
| Dividends: | The Company has not paid any cash dividends since incorporation. The Company does not anticipate paying dividends in the foreseeable future. |
